These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 36150263

  • 1. Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years.
    Oship D, Jakimovski D, Bergsland N, Horakova D, Uher T, Vaneckova M, Havrdova E, Dwyer MG, Zivadinov R.
    Mult Scler Relat Disord; 2022 Nov; 67():104187. PubMed ID: 36150263
    [Abstract] [Full Text] [Related]

  • 2. A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.
    Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):446-452. PubMed ID: 30819766
    [Abstract] [Full Text] [Related]

  • 3. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [Abstract] [Full Text] [Related]

  • 4. Enlarged choroid plexus in multiple sclerosis is associated with increased lesion load and atrophy in white matter but not gray matter atrophy.
    Akaishi T, Fujimori J, Nakashima I.
    Mult Scler Relat Disord; 2024 Feb; 82():105424. PubMed ID: 38181695
    [Abstract] [Full Text] [Related]

  • 5. Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis.
    Bergsland N, Dwyer MG, Jakimovski D, Weinstock-Guttman B, Zivadinov R.
    J Neuroimaging; 2021 Sep; 31(5):995-1002. PubMed ID: 34081373
    [Abstract] [Full Text] [Related]

  • 6. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.
    Barnett M, Bergsland N, Weinstock-Guttman B, Butzkueven H, Kalincik T, Desmond P, Gaillard F, van Pesch V, Ozakbas S, Rojas JI, Boz C, Altintas A, Wang C, Dwyer MG, Yang S, Jakimovski D, Kyle K, Ramasamy DP, Zivadinov R.
    Neuroimage Clin; 2021 Sep; 32():102802. PubMed ID: 34469848
    [Abstract] [Full Text] [Related]

  • 7. Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
    Bergsland N, Dwyer MG, Jakimovski D, Tavazzi E, Benedict RHB, Weinstock-Guttman B, Zivadinov R.
    Neurology; 2023 Feb 28; 100(9):e911-e920. PubMed ID: 36543575
    [Abstract] [Full Text] [Related]

  • 8. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH.
    Brain; 2008 Mar 28; 131(Pt 3):808-17. PubMed ID: 18234696
    [Abstract] [Full Text] [Related]

  • 9. Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis.
    Giorgio A, Stromillo ML, Bartolozzi ML, Rossi F, Battaglini M, De Leucio A, Guidi L, Maritato P, Portaccio E, Sormani MP, Amato MP, De Stefano N.
    Mult Scler; 2014 Feb 28; 20(2):214-9. PubMed ID: 23877971
    [Abstract] [Full Text] [Related]

  • 10. Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple Sclerosis.
    Cagol A, Ocampo-Pineda M, Lu PJ, Weigel M, Barakovic M, Melie-Garcia L, Chen X, Lutti A, Calabrese P, Kuhle J, Kappos L, Sormani MP, Granziera C.
    Neurol Neuroimmunol Neuroinflamm; 2024 Nov 28; 11(6):e200299. PubMed ID: 39270143
    [Abstract] [Full Text] [Related]

  • 11. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Datta G, Colasanti A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, Nicholas R, Van Vlierberghe E, Van Hecke W, Searle G, Santos-Ribeiro A, Matthews PM.
    Brain; 2017 Nov 01; 140(11):2927-2938. PubMed ID: 29053775
    [Abstract] [Full Text] [Related]

  • 12. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
    Calvi A, Tur C, Chard D, Stutters J, Ciccarelli O, Cortese R, Battaglini M, Pietroboni A, De Riz M, Galimberti D, Scarpini E, De Stefano N, Prados F, Barkhof F.
    Neuroimage Clin; 2022 Nov 01; 35():103048. PubMed ID: 35598462
    [Abstract] [Full Text] [Related]

  • 13. Vascular disease risk factors in multiple sclerosis: Effect on metabolism and brain volumes.
    Sammi MK, Fryman A, Baker E, Moloney B, Powers K, West R, Bittner F, Lane M, Martin K, Pepelyayeva Y, Anderson VC, Rooney WD, Yadav V.
    Mult Scler Relat Disord; 2023 Jun 01; 74():104675. PubMed ID: 37121104
    [Abstract] [Full Text] [Related]

  • 14. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, Vaneckova M, Zivadinov R.
    J Neurol Sci; 2009 Jul 15; 282(1-2):112-9. PubMed ID: 19168190
    [Abstract] [Full Text] [Related]

  • 15. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
    Stevenson VL, Smith SM, Matthews PM, Miller DH, Thompson AJ.
    J Neurol; 2002 Feb 15; 249(2):171-7. PubMed ID: 11985382
    [Abstract] [Full Text] [Related]

  • 16. Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.
    Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.
    J Neuroimaging; 2019 Sep 15; 29(5):615-623. PubMed ID: 31259467
    [Abstract] [Full Text] [Related]

  • 17. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
    Jiang T, Ziemssen T, Wray S, Shen C, Söderbärg K, Lewin JB, Božin I, Freedman MS.
    CNS Drugs; 2023 May 15; 37(5):441-452. PubMed ID: 37155132
    [Abstract] [Full Text] [Related]

  • 18. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    J Neurol Neurosurg Psychiatry; 2001 Jun 15; 70(6):773-80. PubMed ID: 11385012
    [Abstract] [Full Text] [Related]

  • 19. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D.
    Mult Scler; 2016 Nov 15; 22(13):1709-1718. PubMed ID: 26883943
    [Abstract] [Full Text] [Related]

  • 20. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.
    Jacobsen C, Hagemeier J, Myhr KM, Nyland H, Lode K, Bergsland N, Ramasamy DP, Dalaker TO, Larsen JP, Farbu E, Zivadinov R.
    J Neurol Neurosurg Psychiatry; 2014 Oct 15; 85(10):1109-15. PubMed ID: 24554101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.